Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENYLBUTAZONE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Relief of pain and inflammation in ankylosing spondylitis,Acute gouty arthritis,Osteoarthritis,Rheumatoid arthritis (short-term management),Off-label: Use in veterinary medicine for musculoskeletal disorders
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic metabolism via CYP2C9 and CYP3A4; major metabolite is oxyphenbutazone; minor pathways include hydroxylation and glucuronidation.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
98–99% bound, primarily to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.05–0.1 L/kg, indicating limited extravascular distribution; increased in hypoalbuminemia.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 100% absorbed, though systemic availability may be reduced by first-pass metabolism (bioavailability ~90%). Intramuscular: near 100%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 10-50: use 50% of normal dose. GFR <10: contraindicated due to accumulation of active metabolite oxyphenbutazone.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated due to risk of hepatotoxicity.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not recommended in children under 14 years due to risk of Reye-like syndrome and hypersensitivity; safety and efficacy not established.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at lowest effective dose (100 mg once or twice daily); monitor closely for fluid retention, GI bleeding, and renal impairment; avoid long-term use.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
WARNING: Aplastic anemia, agranulocytosis, and other blood dyscrasias have been associated with phenylbutazone. Use only when other NSAIDs have failed due to serious adverse effects. Monitor blood counts regularly. Risk is dose-related and increased with prolonged use.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of bone marrow suppression (aplastic anemia, agranulocytosis); gastrointestinal ulceration and bleeding; renal toxicity (especially in elderly, dehydrated, or those with pre-existing renal impairment); hepatic dysfunction; hypersensitivity reactions; sodium and water retention; increased cardiovascular risk; use lowest effective dose for shortest duration.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to phenylbutazone or other NSAIDs; history of aplastic anemia or agranulocytosis; active peptic ulcer disease; severe renal or hepatic impairment; advanced age; concomitant use with other NSAIDs or anticoagulants; pregnancy (third trimester) and lactation.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid taking with alcohol as it may increase the risk of gastrointestinal bleeding and hepatotoxicity. Grapefruit juice may increase drug levels and toxicity; avoid concurrent consumption. High-fat meals can delay but do not significantly reduce absorption; take with food or milk to minimize gastrointestinal irritation. Maintain adequate hydration unless contraindicated due to fluid retention concerns.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Increased risk of cardiovascular malformations and neural tube defects due to inhibition of prostaglandin synthesis. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Avoid in all trimesters unless absolutely necessary.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted into breast milk in low concentrations. M/P ratio is approximately 0.1–0.2. Potential for adverse effects in the infant, including platelet dysfunction and renal impairment. Avoid breastfeeding during therapy.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Increased renal clearance and volume of distribution in pregnancy may reduce serum drug levels. However, due to significant teratogenic and fetal risks, use is contraindicated in pregnancy. No dosing adjustment justified.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) with potent anti-inflammatory, antipyretic, and analgesic effects, but its use is severely limited due to high risk of serious adverse effects including agranulocytosis, aplastic anemia, and hepatotoxicity. It is reserved for short-term treatment of severe conditions such as ankylosing spondylitis, acute gouty arthritis, and acute exacerbations of rheumatoid arthritis when other therapies are ineffective or contraindicated. Due to its long half-life (50-100 hours), dosing should be carefully adjusted, and complete blood counts (CBC) and liver function tests must be monitored regularly. It inhibits prostaglandin synthesis and can cause sodium and water retention, exacerbating hypertension and heart failure. Avoid concomitant use with other NSAIDs, anticoagulants, or methotrexate due to increased bleeding risk and toxicity.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take this medication exactly as prescribed; do not exceed the recommended dose or duration of therapy due to risk of serious side effects.,Report any signs of infection (fever, sore throat, mouth ulcers), unusual bleeding or bruising, skin rash, or jaundice immediately.,Avoid alcohol and aspirin-containing products while taking this drug.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Use effective contraception if you are of childbearing age; this drug may be harmful to an unborn baby and should not be used in late pregnancy.,Do not take this drug with other NSAIDs (e.g., ibuprofen, naproxen) or corticosteroids without consulting your doctor.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"The combination of fenoprofen, a nonsteroidal anti-inflammatory drug (NSAID), with phenylbutazone, another NSAID with potent anti-inflammatory effects, significantly increases the risk of gastrointestinal (GI) adverse effects, including ulceration, bleeding, and perforation. This additive toxicity arises from synergistic inhibition of cyclooxygenase (COX) enzymes, leading to reduced gastroprotective prostaglandin synthesis and impaired platelet aggregation. Clinically, patients may experience increased incidence of gastric mucosal injury, occult blood loss, and potentially life-threatening GI bleeding, particularly in elderly or renally impaired individuals."
"Aprepitant, a moderate CYP3A4 inducer, can accelerate the metabolism of Phenylbutazone, a nonsteroidal anti-inflammatory drug (NSAID) primarily metabolized by CYP3A4 and CYP2C9. This leads to reduced plasma concentrations of Phenylbutazone, potentially diminishing its analgesic and anti-inflammatory efficacy. The interaction may result in inadequate symptom control in patients with chronic inflammatory conditions such as rheumatoid arthritis."
"Phenylbutazone, a nonsteroidal anti-inflammatory drug (NSAID) with potent prostaglandin synthesis inhibition, antagonizes the vasodilatory and antiplatelet effects of epoprostenol, a prostacyclin analog. This occurs because phenylbutazone reduces the production of endogenous prostacyclin and may also compete for receptor binding or downstream signaling, thereby diminishing epoprostenol's therapeutic efficacy in pulmonary arterial hypertension. Clinically, this interaction may lead to increased pulmonary vascular resistance, worsening symptoms, and elevated risk of thrombotic events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENYLBUTAZONE vs ACTIQ, answered by our medical review team.
PHENYLBUTAZONE is a NSAID that works by Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENYLBUTAZONE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENYLBUTAZONE is: Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENYLBUTAZONE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENYLBUTAZONE is classified as Category C. First trimester: Increased risk of cardiovascular malformations and neural tube defects due to inhibition of prostaglandin synthesis. Second and third trimesters: Risk of premature. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.